Oral vinorelbine in the treatment of non-small-cell lung cancer

Bibliography

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Grossi F, Aita M, Defferrari C, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009;14(5):497-510
   PubMed Web of Science ®Google Scholar
• Himes RH. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 1991;51(2):257-67
   PubMed Web of Science ®Google Scholar
• Toso RJ, Jordan MA, Farrell KW, et al. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 1993;32(5):1285-93
   Google Scholar
• Capasso A. Vinorelbine in cancer therapy. Curr Drug Targets 2012;13(8):1065-71
   PubMed Web of Science ®Google Scholar
• Caffo O, Dipasquale M, Murgia V, et al. An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. Expert Opin Drug Metab Toxicol 2013;9(8):1037-51
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Gatzemeier U, Gebbia V, et al. Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 2007;67(10):1403-10
   PubMed Web of Science ®Google Scholar
• Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001;12(11):1643-9
   PubMed Web of Science ®Google Scholar
• Bourgeois H, Vermorken J, Dark G, et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol 2007;60(3):407-13
   Google Scholar
• Chevallier B, Bonneterre J, Lebras F. Phase I trial of oral vinorelbine in patients with advanced breast cancer. Br J Cancer 1997;75:45
   Google Scholar
• Depierre A, Freyer G, Jassem J, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001;12(12):1677-81
   Google Scholar
• Jassem J, Ramlau R, Karnicka-Młodkowska H, et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001;12(10):1375-81
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552-9
   PubMed Web of Science ®Google Scholar
• Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010;5(2):220-8
   PubMed Web of Science ®Google Scholar
• Pender A, Coward J, Gunapala R, et al. Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC). Lung Cancer 2013;79(s2):S12. Presented at the 11th Annual BTOG conference; 23 – 25 January 2013; Dublin, Ireland
   Google Scholar
• Magnet FS, Alten N, Bachinger A, et al. Adjuvant treatment of completely resected stage IB-IIIA non-small-cell lung cancer. A retrospective study with cisplatin or carboplatin and oral vinorelbine. J Clin Oncol 2014;32(Suppl):abstract e18505. Published in conjunction with the 2014 ASCO Annual Meeting; 30 May – 3 June 2014; Chicago, Illinois
   Google Scholar
• Kolek V, Grygarkova I, Chalupa J, et al. Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemo- therapy of non-small cell lung cancer: a prospective multicentre study of tolerability and survival. J Thorac Oncol 2013;8(Suppl):abstract P1.12-009. Presented at the 15th World Conference on Lung Cancer; 27 – 30 October 2013; Sidney
   Google Scholar
• Bayman NA, Blackhall F, Jain P, et al. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 2008;9(2):92-101
   Google Scholar
• Beckmann G, Fietkau R, Huber RM, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study. Onkologie 2006;29(4):137-42
   Google Scholar
• Krzakowski M, Provencio M, Utracka-Hutka B, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol 2008;3(9):994-1002
   Google Scholar
• Descourt R, Vergnenegre A, Barlesi F, et al. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. J Thorac Oncol 2011;6(2):351-7
   Google Scholar
• Singhal N, Pittman KB, Karapetis CS, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): COVeRT study. J Clin Oncol 2012; 30(Suppl):abstract e17544. Published in conjunction with the 2012 ASCO Annual Meeting; 1–5 June 2012; Chicago, Illinois
   Google Scholar
• Huber RM, Engel-Riedel W, Kollmeier J, et al. GILT study: oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. J Clin Oncol 2012;30(Suppl):abstract 7001. Presented at the 2012 ASCO Annual Meeting; 1 – 5 June 2012; Chicago, Illinois
   Google Scholar
• Lerouge D, Rivière A, Dansin E, et al. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer 2014;14(1):231. [ Epub ahead of print]
   Google Scholar
• Schwarzenberger P, Fariss A, Linares L, et al. Dose escalation of once weekly oral vinorelbine concurrent with weekly split dose hypofractionated chest radiation for palliation of advanced non-small cell lung cancer: a phase I/II study. Am J Med Sci 2011;341(6):454-9
   Google Scholar
• Delord JP, Puozzo C, Lefresne F, Bugat R. Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors. Anticancer Res 2009;29(2):553-60
   PubMed Web of Science ®Google Scholar
• Jassem J, Kosmidis P, Ramlau R, et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 2003;14(11):1634-9
   PubMed Web of Science ®Google Scholar
• Campagnoli E, Garassino I, Santoro A, et al. Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer. Invest New Drugs 2007;25(6):559-64
   Google Scholar
• Martoni AA, Melotti B, Sperandi F, et al. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study. Lung Cancer 2008;60(3):387-92
   Google Scholar
• O’Brien ME, Szczesna A, Karnicka H, et al. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 2004;15(6):921-7
   PubMed Web of Science ®Google Scholar
• Alici S, Coskun U, Alkis N, et al. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas. Asian Pac J Cancer Prev 2009;10(6):1051-5
   Google Scholar
• Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62(1):85-91
   PubMed Web of Science ®Google Scholar
• Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009;20(7):1249-56
   PubMedGoogle Scholar
• Lena MD, Ramlau R, Hansen O, et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 2005;48(1):129-35
   Google Scholar
• Reck M, Macha HN, Del Barco S, et al. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 2009;64(3):319-25
   Google Scholar
• Reinmuth N, Meyer A, Hartwigsen D, et al. Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer 2014;83(3):363-8
   Google Scholar
• Bennouna J, Havel L, Krzakowski M, et al. Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: Final results. J Clin Oncol 2013;31(suppl):abstr 8043. Presented at the 2013 ASCO Annual Meeting; 30 May – 4 June 2013; Chicago, Illinois
   Google Scholar
• Chen YM, Yu CJ, Yang CH, et al. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 2007;56(1):89-95
   Google Scholar
• Hirsh V, Desjardins P, Needles BM, et al. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): a randomized phase II trial. Am J Clin Oncol 2007;30(3):245-51
   Google Scholar
• Rossi D, Catalano V, Alessandroni P, et al. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer. Clin Lung Cancer 2007;8(6):382-5
   Google Scholar
• Pallis AG, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 2014. [ Epub ahead of print]
   Google Scholar
• Meoni G, Cecere FL, Lucherini E, Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents. J Geriatr Oncol 2013;4(3):282-90
   PubMed Web of Science ®Google Scholar
• Kanard A, Jatoi A, Castillo R, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 2004;43(3):345-53
   PubMed Web of Science ®Google Scholar
• Gridelli C, Manegold C, Mali P, et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 2004;40(16):2424-31
   Google Scholar
• Chen YM, Tsai CM, Fan WC, et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 2012;7(2):412-18
   PubMed Web of Science ®Google Scholar
• Kosmidis PA, Syrigos K, Kalofonos HP, et al. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2. Anticancer Res 2012;32(1):175-81
   Google Scholar
• Camerini A, Valsuani C, Mazzoni F, et al. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol 2010;21(6):1290-5
   Google Scholar
• Collovà E, Sebastiani F, De Matteis E, et al. Use of metronomic chemotherapy in oncology: results from a national Italian survey. Tumori 2011;97(4):454-8
   Google Scholar
• Lien K, Georgsdottir S, Sivanathan L, et al. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 2013;49(16):3387-95
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Pappas P, Puozzo C, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 2009;15(20):6454-61
   PubMed Web of Science ®Google Scholar
• Rajdev L, Negassa A, Dai Q, et al. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol 2011;68(5):1119-24
   Google Scholar
• Tufman A, Borgmeier A, Guetz S, et al. Treatment of advanced recurrent NSCLC with daily oral vinorelbine: A phase I trial. J Clin Oncol 2013;31(suppl):abstr e19108. Presented at the 2013 ASCO Annual Meeting, 30 May – 4 June 2013; Chicago, Illinois
   Google Scholar
• Pallis AG, Chandrinos V, Pavlakou G, et al. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Cancer Chemother Pharmacol 2011;67(6):1239-45
   Google Scholar
• Kontopodis E, Hatzidaki D, Varthalitis I, et al. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother 2013;25(1):49-55
   PubMed Web of Science ®Google Scholar
• Lewis JR, Lipworth WL, Kerridge IH, Day RO. The economic evaluation of personalised oncology medicines: ethical challenges. Med J Aust 2013;199(7):471-3
   Google Scholar
• Grossi F, Genova C, Gaitan ND, et al. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. Lung Cancer 2013;81(2):236-40
   Google Scholar
• Le Lay K, Myon E, Hill S, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007;8(2):145-51
   Google Scholar
• Grossi F, Buffoni L, Favaretto A, et al. Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. PharmacoEcon Ital Res Artic 2014;16(19):1-15; Italian Language
   Google Scholar
• Provencio M, de Las Peñas R, Camps C, et al. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: is a hemogram on day 8 essential? Lung Cancer 2010;68(3):415-19
   PubMed Web of Science ®Google Scholar
• Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005;92(3):265-72
   Google Scholar
• De Pas T, Sbanotto A, Catania C, et al. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. Support Care Cancer 2005;13(3):194-5
   Google Scholar